178 related articles for article (PubMed ID: 38530357)
1. Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
Zhu Y; Banerjee A; Xie P; Ivanov AA; Uddin A; Jiao Q; Chi JJ; Zeng L; Lee JY; Xue Y; Lu X; Cristofanilli M; Gradishar WJ; Henry CJ; Gillespie TW; Bhave MA; Kalinsky K; Fu H; Bahar I; Zhang B; Wan Y
J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38530357
[TBL] [Abstract][Full Text] [Related]
2. Posttranslational protein modifications as gatekeepers of cancer immunogenicity.
Marchese E; Demehri S
J Clin Invest; 2024 May; 134(10):. PubMed ID: 38747288
[TBL] [Abstract][Full Text] [Related]
3. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
4. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.
Loi S; Pommey S; Haibe-Kains B; Beavis PA; Darcy PK; Smyth MJ; Stagg J
Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11091-6. PubMed ID: 23776241
[TBL] [Abstract][Full Text] [Related]
5. CD73: an emerging checkpoint for cancer immunotherapy.
Chen S; Wainwright DA; Wu JD; Wan Y; Matei DE; Zhang Y; Zhang B
Immunotherapy; 2019 Aug; 11(11):983-997. PubMed ID: 31223045
[TBL] [Abstract][Full Text] [Related]
6. CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer.
Petruk N; Tuominen S; Åkerfelt M; Mattsson J; Sandholm J; Nees M; Yegutkin GG; Jukkola A; Tuomela J; Selander KS
Sci Rep; 2021 Mar; 11(1):6035. PubMed ID: 33727591
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy induces enrichment of CD47
Samanta D; Park Y; Ni X; Li H; Zahnow CA; Gabrielson E; Pan F; Semenza GL
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1239-E1248. PubMed ID: 29367423
[TBL] [Abstract][Full Text] [Related]
8. Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function.
Jin R; Liu L; Xing Y; Meng T; Ma L; Pei J; Cong Y; Zhang X; Ren Z; Wang X; Shen J; Yu K
Mol Cancer Ther; 2020 Nov; 19(11):2340-2352. PubMed ID: 32943546
[TBL] [Abstract][Full Text] [Related]
9. CD73-adenosine: a next-generation target in immuno-oncology.
Allard D; Allard B; Gaudreau PO; Chrobak P; Stagg J
Immunotherapy; 2016 Feb; 8(2):145-63. PubMed ID: 26808918
[TBL] [Abstract][Full Text] [Related]
10. Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity.
Fu Z; Chen S; Zhu Y; Zhang D; Xie P; Jiao Q; Chi J; Xu S; Xue Y; Lu X; Song X; Cristofanilli M; Gradishar WJ; Kalinsky K; Yin Y; Zhang B; Wan Y
Sci Adv; 2023 Jan; 9(1):eadd6626. PubMed ID: 36608132
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of CD73 associates with T cell exhaustion in AML patients.
Kong Y; Jia B; Zhao C; Claxton DF; Sharma A; Annageldiyev C; Fotos JS; Zeng H; Paulson RF; Prabhu KS; Zheng H
J Hematol Oncol; 2019 Apr; 12(1):40. PubMed ID: 31014364
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
Buisseret L; Pommey S; Allard B; Garaud S; Bergeron M; Cousineau I; Ameye L; Bareche Y; Paesmans M; Crown JPA; Di Leo A; Loi S; Piccart-Gebhart M; Willard-Gallo K; Sotiriou C; Stagg J
Ann Oncol; 2018 Apr; 29(4):1056-1062. PubMed ID: 29145561
[TBL] [Abstract][Full Text] [Related]
13. CD73 contributes to anti-inflammatory properties of afferent lymphatic endothelial cells in humans and mice.
Eichin D; Pessia A; Takeda A; Laakkonen J; Bellmann L; Kankainen M; Imhof BA; Stoitzner P; Tang J; Salmi M; Jalkanen S
Eur J Immunol; 2021 Jan; 51(1):231-246. PubMed ID: 32970335
[TBL] [Abstract][Full Text] [Related]
14. CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model.
Tsukui H; Horie H; Koinuma K; Ohzawa H; Sakuma Y; Hosoya Y; Yamaguchi H; Yoshimura K; Lefor AK; Sata N; Kitayama J
BMC Cancer; 2020 May; 20(1):411. PubMed ID: 32397971
[TBL] [Abstract][Full Text] [Related]
15. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
[TBL] [Abstract][Full Text] [Related]
16. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.
Neo SY; Yang Y; Record J; Ma R; Chen X; Chen Z; Tobin NP; Blake E; Seitz C; Thomas R; Wagner AK; Andersson J; de Boniface J; Bergh J; Murray S; Alici E; Childs R; Johansson M; Westerberg LS; Haglund F; Hartman J; Lundqvist A
J Clin Invest; 2020 Mar; 130(3):1185-1198. PubMed ID: 31770109
[TBL] [Abstract][Full Text] [Related]
17. Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches.
Chang HW; Frey G; Liu H; Xing C; Steinman L; Boyle WJ; Short JM
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33627407
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers.
Song X; Zhou Z; Li H; Xue Y; Lu X; Bahar I; Kepp O; Hung MC; Kroemer G; Wan Y
Cancer Discov; 2020 Dec; 10(12):1872-1893. PubMed ID: 32938586
[TBL] [Abstract][Full Text] [Related]
19. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer.
Zhou Q; Ding W; Qian Z; Zhu Q; Sun C; Yu Q; Tai Z; Xu K
Mol Pharm; 2021 Nov; 18(11):4015-4028. PubMed ID: 34648293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
